MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 125681 | Name: Hynic-TOC
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

HYNIC-Tyr3-octreotide, also known as Hynic-TOC, is a ligand for making 99mTc-Hynic-TOC as an imaging agent in the diagnostic of neuroendocrine tumor.

Chemical Structure

Hynic-TOC
Hynic-TOC
CAS#257943-19-4

Theoretical Analysis

MedKoo Cat#: 125681

Name: Hynic-TOC

CAS#: 257943-19-4

Chemical Formula: C55H71N13O12S2

Exact Mass: 1169.4800

Molecular Weight: 1170.37

Elemental Analysis: C, 56.44; H, 6.11; N, 15.56; O, 16.40; S, 5.48

Price and Availability

Size Price Availability Quantity
5mg USD 1,650.00 2 Weeks
10mg USD 2,950.00 2 Weeks
100mg USD 6,950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
HYNIC-Tyr3-octreotide; Hynic-TOC; HynicTOC; Hynic TOC;
IUPAC/Chemical Name
(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-10-(4-aminobutyl)-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-19-((R)-2-((E)-6-hydrazineylidene-1,6-dihydropyridine-3-carboxamido)-3-phenylpropanamido)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
InChi Key
WJBPMDZACHSXSD-HLAGHTPDSA-N
InChi Code
InChI=1S/C55H71N13O12S2/c1-30(70)43(27-69)64-54(79)45-29-82-81-28-44(65-51(76)40(22-32-10-4-3-5-11-32)61-48(73)34-17-20-46(68-57)59-25-34)53(78)62-41(23-33-15-18-36(72)19-16-33)50(75)63-42(24-35-26-58-38-13-7-6-12-37(35)38)52(77)60-39(14-8-9-21-56)49(74)67-47(31(2)71)55(80)66-45/h3-7,10-13,15-20,25-26,30-31,39-45,47,58,69-72H,8-9,14,21-24,27-29,56-57H2,1-2H3,(H,59,68)(H,60,77)(H,61,73)(H,62,78)(H,63,75)(H,64,79)(H,65,76)(H,66,80)(H,67,74)/t30-,31-,39+,40-,41+,42-,43-,44+,45+,47+/m1/s1
SMILES Code
O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](NC(C(C=C/2)=CNC2=N\N)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=C(C=C4)O)N[C@@H]1CC5=CNC6=CC=CC=C56
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,170.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Briganti V, Cuccurullo V, Berti V, Di Stasio GD, Linguanti F, Mungai F, Mansi L. 99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases). Curr Radiopharm. 2020;13(3):166-176. doi: 10.2174/1874471013666191230143610. PMID: 31886756; PMCID: PMC8193811. 2: Garai I, Barna S, Nagy G, Forgacs A. Limitations and pitfalls of 99mTc- EDDA/HYNIC-TOC (Tektrotyd) scintigraphy. Nucl Med Rev Cent East Eur. 2016;19(2):93-8. doi: 10.5603/NMR.2016.0019. PMID: 27479887. 3: Shi X, Jing H, Li F, Zhao Y, Wang Z, Huo L. 99mTc-HYNIC-TOC in the Evaluation of Recurrent Tumor-Induced Osteomalacia. Clin Nucl Med. 2019 Mar;44(3):209-213. doi: 10.1097/RLU.0000000000002458. PMID: 30672760. 4: Li B, Duan L, Li X, Shi J, Li H, Liu H, Cheng X, Wu X, Gao Y. Diagnostic accuracy of 99mTc-HYNIC-TOC SPECT/CT for detecting osteomalacia- associated tumors. Front Oncol. 2023 Jul 24;13:1228575. doi: 10.3389/fonc.2023.1228575. PMID: 37554164; PMCID: PMC10405922. 5: Liepe K, Becker A. 99mTc-Hynic-TOC imaging in the diagnostic of neuroendocrine tumors. World J Nucl Med. 2018 Jul-Sep;17(3):151-156. doi: 10.4103/wjnm.WJNM_41_17. PMID: 30034278; PMCID: PMC6034543. 6: Chaib S, Hallouard F, Chennell P, Darcissac C, Morelec I, Rioufol C, Sautou V, Fraysse M. Compatibility of [99mTc]Tc-EDDA/HYNIC-TOC and [68Ga] Ga-DOTA-TOC in a syringe for intravenous administration. Nucl Med Commun. 2020 Jan;41(1):11-17. doi: 10.1097/MNM.0000000000001108. PMID: 31764593. 7: Hou G, Jiang Y, Li F, Zhu Z, Jing H. Site-based performance of 131I-MIBG imaging and 99mTc-HYNIC-TOC scintigraphy in the detection of nonmetastatic extra-adrenal paraganglioma. Nucl Med Commun. 2022 Jan 1;43(1):32-41. doi: 10.1097/MNM.0000000000001490. PMID: 34570039; PMCID: PMC8654250. 8: Gherghe M, Lazăr AM, Stanciu AE, Mutuleanu MD, Sterea MC, Petroiu C, Galeș LN. The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs? Cancers (Basel). 2022 May 31;14(11):2725. doi: 10.3390/cancers14112725. PMID: 35681704; PMCID: PMC9179571. 9: Sager S, Kabasakal L, Halac M, Maecke H, Uslu L, Önsel Ç, Kanmaz B. Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers. Clin Nucl Med. 2013 May;38(5):321-5. doi: 10.1097/RLU.0b013e3182868062. PMID: 23531772. 10: Boutsikou E, Porpodis K, Chatzipavlidou V, Hardavella G, Gerasimou G, Domvri K, Papadopoulos N, Avramidou V, Spyratos D, Kontakiotis T, Zarogoulidis K. Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819842586. doi: 10.1177/1533033819842586. PMID: 31079574; PMCID: PMC6535698.